MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
1.340
-0.140
-9.46%
Pre Market: 1.360 +0.02 +1.47% 09:09 12/19 EST
OPEN
1.350
PREV CLOSE
1.480
HIGH
1.445
LOW
1.260
VOLUME
25.68K
TURNOVER
0
52 WEEK HIGH
2.010
52 WEEK LOW
0.2425
MARKET CAP
95.42M
P/E (TTM)
-2.6208
1D
5D
1M
3M
1Y
5Y
1D
Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating
TipRanks · 2h ago
RA CAPITAL MANAGEMENT, L.P. REPORTS 9.9% PASSIVE STAKE IN OVID THERAPEUTICS AS OF DEC 11 - SEC FILING
Reuters · 14h ago
Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward
TipRanks · 22h ago
Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data
TipRanks · 1d ago
Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Neural Hyperexcitability
Reuters · 1d ago
OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026
Reuters · 1d ago
Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV
TipRanks · 1d ago
Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071
Reuters · 1d ago
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.